How to use monoclonal antibodies for migraine in primary care
UC migraine expert featured in Medscape article
The University of Cincinnati's Vincent Martin told Medscape that every primary care clinician should know about monoclonal antibodies for preventing migraines that are changing the lives of patients.
"These should be primary care meds," said Martin, MD, professor in the Department of Internal Medicine in UC's College of Medicine and director of the Headache and Facial Pain Center at the University of Cincinnati Gardner Neuroscience Institute. Physicians using the calcitonin gene-related peptide (CGRP) monoclonal antibodies "can dramatically improve the quality of their migraine patients just by learning how to use this group of medications," he continued.
Martin said many of his patients who couldn't tolerate or had inadequate repsponses to conventional migraine medications are now doing very well with CGRP agents.
"The old, conventional preventive therapies took 1-3 months to work. In some instances, these medications can work in a week or less — their onset of action is much quicker," Martin said.
Featured photo at top of a woman with a headache. Photo/FG Trade/iStock.
Related Stories
Pocket-sized population threat
May 18, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
UC finds integrating substance use disorder treatment into clinic-based internal medicine expands access to care
May 18, 2026
A University of Cincinnati primary care teaching clinic integrates substance use disorder treatment into resident training, expanding access to addiction care and boosting physician confidence.
Colorado silica dust trial could change the way industry does business
May 17, 2026
Betsy Malloy, Andrew Katsanis Professor of Law, at the University of Cincinnati, spoke with Bloomberg Law about how a Colorado trial could change the way the stone fabrication industry does business.